

Committee for Risk Assessment
RAC

Annex 3
Records

of the targeted public consultation following the submission of additional studies addressing the classification for reproductive toxicity

clomazone (ISO); 2-(2-chlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one

EC Number: -
CAS Number: 81777-89-1

CLH-O-0000006701-78-01/F

Adopted
20 September 2019

ANNEX 3 - RECORDS OF THE TARGETED PUBLIC CONSULTATION ON CLOMAZONE (ISO); 2-(2-CHLOROBENZYL)-4,4-DIMETHYL-1,2-OXAZOLIDIN-3-ONE

COMMENTS AND RESPONSE TO COMMENTS ON CLH: PROPOSAL AND JUSTIFICATION

The proposal for the harmonised classification and labelling (CLH) of (clomazone (ISO); 2-(2-chlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one, EC 617-258-0; CAS 81777-89-1) was submitted by the Denmark and was subject to a public consultation, from 26/11/2018 to 08/02/2019. The comments received by that date are compiled in Annex 2 to the opinion.

However, during the public consultation of the CLH report, industry provided the study reports from a recently completed developmental toxicity study conducted using Wistar Han rats as well as the relevant dose-range finding study and a toxicokinetic study. In order to clarify the potential impact of the findings of the newly submitted studies on the classification proposal for reproductive toxicity of clomazone (ISO); 2-(2-chlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one, OECD tier 2 summaries of these study reports, as well as industry comments provided on the classification proposed in the CLH report, were therefore subjected to a targeted public consultation. A target consultation was launched from 27/05/2019 to 10/06/2019 and the comments received are listed below.

ECHA accepts no responsibility or liability for the content of this table.

Substance name: clomazone (ISO); 2-(2-chlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one
EC number: -
CAS number: 81777-89-1
Dossier submitter: Denmark

GENERAL COMMENTS

Date	Country	Organisation	Type of Organisation	Comment number
09.06.2019	Denmark		Individual	1
Comment received				
Have followed the process for different substances there appear to be an increasing trend that industry again and again attempt to dilute existing data sets by presenting new studies to overrule the findings in existing studies. I urge the evaluators and RAC decision makers to stand by the science, and not be misled by these attempts. The comments by the Chairman for the substance mancozeb at RAC 48 were appreciated in the sense that the RAC stood by the scientific evidence of the "old" studies, despite the attempt of industry to disqualify the "old" studies by presenting new studies. Dear evaluators; you have a huge responsibility to protect us all from dangerous substances. The studies already evaluated and found scientific robust for clomazone provide evidence of it's reproductive harm to humans. Please, do not let yourself be misled by industry's strategy to again and again present new studies. Keep in mind that the findings of the existing studies do not disappear.				
RAC's response				
Noted, thank you.				

TOXICITY TO REPRODUCTION

Date	Country	Organisation	Type of Organisation	Comment number
08.06.2019	United States	FMC Corporation	Company-Manufacturer	2
Comment received				
CLOMAZONE (EC/List No. 617-258-0; CAS No. 81777-89-1) Comments on Proposed Classification – Targeted Public Consultation				

ANNEX 3 - RECORDS OF THE TARGETED PUBLIC CONSULTATION ON CLOMAZONE (ISO); 2-(2-CHLOROBENZYL)-4,4-DIMETHYL-1,2-OXAZOLIDIN-3-ONE

Submitted by the FMC Corporation
June 7, 2019

FMC strongly disagrees with the proposal to classify Clomazone for developmental toxicity Repr. 1B, H360D and has submitted a new guideline compliant (OECD 414 & OPPTS 870.370) rat pre-natal developmental toxicity study (2019) along with an in-depth review of one of two earlier studies (2002) in rats that purported an increase in limb flexures characterised as "arthrogryposis" in high dose fetuses – both the subject of this targeted public consultation. The observed skeletal findings of "arthrogryposis" in the earlier 2002 study are considered artefacts incurred during foetal processing, and therefore no conclusions can be drawn from this study for purposes of classification.

The reproduction and developmental toxicity data package for Clomazone now consists of five pre-natal developmental toxicity studies – three in rats and two in rabbits, as well as a multigeneration reproduction study. On the basis of these studies, the following conclusions regarding the potential of Clomazone to cause adverse effects on the developing foetus can be made:

1. There is no evidence of reproductive or developmental toxicity from a two generation reproduction study in Charles River CD rats (1984).

2. There is no evidence of pre-natal developmental toxicity from a study in Sprague Dawley rats (1984).

3. Highly doubtful evidence of "arthrogryposis" was reported in a deficient, unreliable pre-natal developmental study in Wistar rats (2002).

a. One of the most significant discrepancies in this study is the disconnect between the recording of external and skeletal findings suggesting that the noted skeletal finding of "arthrogryposis" was a result of artefacts induced during foetal handling. A single foetus in the high dose group of the main study (750 mg/kg-bw/day) was noted as having "forelimbs flexed at the wrist" during external examination, which was not confirmed on skeletal examination. However, 7 fetuses were reported as having "arthrogryposis" in the same dose group at skeletal examination. True instances of pathological limb flexure should have been evident externally and during skeletal examination. This significant discrepancy between the external and skeletal examination seriously calls into question the reliability of the skeletal findings.

b. No incidence of limb flexure ("arthrogryposis") was evident in the fetuses from the dose range finding study conducted in advance of the main study – up to a much higher dose level of 1,000 mg/kg-bw/day.

c. "Arthrogryposis" represents an interpretation by the laboratory of some degree of joint flexure, a term which was not listed in the protocol for foetal skeletal evaluations in this study (Study Appendix 15). Based on information provided by the testing laboratory, arthrogryposis was defined as "persistent flexure or contracture of a joint flexed paw (bent or twist)" which included flexures of even mild severity.

d. The term "arthrogryposis" appears to have been used in an unconventional manner by the laboratory at the time of study conduct. Arthrogryposis is a diagnostic term that refers to joint contractures that develop before birth, are evident at birth and are characterized by reduced mobility of multiple joints as a result of impaired connective tissue development. Any true case of arthrogryposis seen in a pre-natal developmental toxicity study should have been present at the time of fresh foetal examination and would have been confirmed by gentle pressure to the joint to determine if it was in a genuinely fixed state.

e. The logical conclusion is that the recorded findings of "arthrogryposis" in the 2002 Wistar rat developmental toxicity study are artefacts resulting from improper foetal processing procedures (e.g., limb joint bending resulting from "heavy handed" or

ANNEX 3 - RECORDS OF THE TARGETED PUBLIC CONSULTATION ON CLOMAZONE (ISO); 2-(2-CHLOROBENZYL)-4,4-DIMETHYL-1,2-OXAZOLIDIN-3-ONE

incomplete foetal skinning practices). Once placed in fixative, the joints would have been fixed in the position they were at the time of handling or the position they assumed in the storage jar. The fact that none of the incidences of "arthrogryposis" reported on skeletal examination were identified on external examination supports this conclusion. It has been reported that artefacts resulting from less than optimal foetal processing procedures can be mis-identified as malformations by inexperienced investigators (Principles and Methods of Toxicology, 5th Edition, edited by Wallace Hayes, page 1681). External experts in the field of developmental toxicity with which FMC has consulted have arrived at the same conclusion regarding the purported finding of "arthrogryposis" in the 2002 Wistar rat pre-natal developmental toxicity study (see Public Comments to CLH Proposal; Comments Nos. 9 and 19).

f. Further, the GLP compliance statement contains a significant GLP deviation noting that the study was conducted in compliance with OECD GLPs and OECD and EPA testing guidelines with the exception that "...evaluation which was conducted with the knowledge of treatment groups". This further suggests that the laboratory did not have much experience with undertaking pre-natal developmental toxicity studies at the time when this study was carried out and evaluator bias may have been a relevant factor in the results of the study.

4. There is no evidence of pre-natal developmental toxicity in a recently conducted, statistically enhanced study in Wistar rats (2019). This is the only study in the pre-natal development dataset conducted according to the current recommended guideline (OECD 414 & OPPTS 870.3700).

a. Given the concerns regarding the conduct of the Wistar rat pre-natal developmental toxicity study (2002), and the fact that the foetal specimens from the study were no longer available for possible re-evaluation, a third rat pre-natal developmental toxicity study was undertaken by a highly experienced and proficient contract research organisation. In preparation for the definitive rat pre-natal developmental toxicity study, a study characterising the toxicokinetic properties of Clomazone over the dose range relevant to the proposed new study was conducted. In addition, a dose range finding study preceded the definitive study. Summaries of these studies are the subject of this targeted public consultation.

b. A comparable strain of rat (Wistar), dosing vehicle (0.5 % carboxymethyl cellulose and 0.1% Tween® 80) and route of administration (oral gavage once daily) were used to permit a direct comparison to the previous study (2002).

c. Four dose levels (100, 250, 500 and 750 mg/kg-bw/day) were included to characterise any dose-response relationship and provide a data-rich data set. The three highest dose levels (250, 500 and 750 mg/kg-bw/day) matched those used in the earlier study (2002). Dose levels were confirmed based on a thorough dose range finding study and using internal dose information from the toxicokinetic study (e.g., plateau of internal dose at 500 mg/kg-bw). The dosing period (Gestation Days 6-20) was for one additional day not covered in the 2002 study (Gestation Days 6-19).

d. Parameters and end points evaluated included clinical signs, body weights, body weight gains, gravid uterine weights, food consumption, gross necropsy, liver weights, intrauterine growth and survival, and foetal morphology (external, visceral and skeletal examination).

e. All fetuses were subject to foetal morphology (including skeletal) assessment, thereby increasing the statistical power compared to the earlier study (2002) where only half the fetuses were subjected to visceral examination and half to skeletal examination. Foetal examinations were conducted without knowledge of treatment group to avoid evaluator bias.

f. Foetal specimens were handled and processed in compliance with the laboratory standard operating procedures in such a way as to minimize foetal artefacts or

ANNEX 3 - RECORDS OF THE TARGETED PUBLIC CONSULTATION ON CLOMAZONE (ISO); 2-(2-CHLOROBENZYL)-4,4-DIMETHYL-1,2-OXAZOLIDIN-3-ONE

mechanically induced alterations. Further, all malformations were verified by a second evaluator. External examination of fresh foetuses included evaluation of the limbs for size, shape and position; feet were examined for carpal/tarsal flexure. A conventional and best practice lexicon to record foetal pathology findings was used (i.e., diagnostic terminology such as "arthrogryposis" was not utilised).

g. The findings in the study included the following:

- Intermittent instances of dilated pupils in the dams between 2-6 hours post dosing occurred at 500 and 750 mg/kg-bw/day.
- Statistically significant and adverse decreases in mean body weight gain (13%) and mean net (minus the products of conception) body weight gain (25%) occurred in the 750 mg/kg-bw/day group relative to the control group.
- Statistically significant increases in liver weights were 11%, 25%, and 23% in the 250, 500 and 750 mg/kg-bw/day groups, respectively, relative to the control group.
- Foetal intrauterine growth and survival and foetal morphology was unaffected by maternal treatment with Clomazone.
- No impact of treatment was observed on mean litter proportions of pre- and post-implantation loss, early, late and total resorptions, mean number and percentage of viable foetuses, mean foetal weight, and foetal sex ratios.
- No incidences of limb flexure were observed in any test-substance treated group either on external or skeletal examination.

5. Results of the rat toxicokinetic study (2019), measuring both total radioactivity and clomazone levels directly following ¹⁴C-labelled test substance, demonstrated saturation of plasma concentrations in female Wistar rats at 500 mg/kg-bw and above indicating oral doses above this dose do not increase internal systemic exposure. This observation has relevance to any interpretation of possible dose-response relationships above this dose.

6. There is no evidence of pre-natal developmental toxicity in a 1982 study in New Zealand white rabbits.

7. There is no evidence of pre-natal developmental toxicity from a second study in New Zealand white rabbits (2002).

a. In the dose range finding study for this rabbit developmental toxicity study, there were 4 foetuses in the control group (8% of all foetuses examined in that group) recorded as having "arthrogryposis". There were no findings of "arthrogryposis" in the treated groups up to and including a high dose level of 1000 mg/kg-bw/day.

b. In the main study, a single foetus in the high dose group demonstrated several frank developmental abnormalities (i.e., acephalaostomia, microtia and forelimb ectodactyly) which also included limb abnormalities. Given the severity of the abnormalities, it is not unexpected to see contractural abnormalities in the limbs. Therefore, this severely malformed foetus should be excluded from further consideration for classification purposes.

c. One other foetus in the high dose group of the main study was recorded as having "both forelimbs flexed at wrist" during external examination; such an observation was not observed during skeletal examination for this foetus.

d. Incidences of malformations – including "arthrogryposis" – in the 2002 rabbit developmental study are within historical control ranges. The single incidence of flexed forelimbs noted above should not be considered as a treatment related finding, particularly given a much greater incidence in control rabbits in general and in the control animals of the accompanying range-finder study.

Conclusions:

ANNEX 3 - RECORDS OF THE TARGETED PUBLIC CONSULTATION ON CLOMAZONE (ISO); 2-(2-CHLOROBENZYL)-4,4-DIMETHYL-1,2-OXAZOLIDIN-3-ONE

1. The 2002 pre-natal developmental toxicity study in Wistar rats is considered methodologically deficient: robust conclusions cannot be drawn from the study.
2. Limb flexures that are not apparent during external examination and then “appear” during skeletal examination do not conform to how genuine developmental effects manifest, but rather reflect inadequate foetal processing and recording practices. The discrepancy between the external and skeletal findings calls into question the reliability of the study.
3. All other studies demonstrate a lack of developmental effects that would warrant classification.
4. The weighting that should be ascribed – within a weight of evidence assessment – to the recent 2019 rat pre-natal developmental toxicity study should be significant given the known quality and capability of the laboratory, procedures to avoid artefacts in foetal processing and number of foetuses subject to morphological assessment. This new study provides high quality, reliable data upon which reproductive toxicity classification can be determined.
5. A comprehensive review of the updated dataset cannot establish that there is “...clear evidence of an adverse effect on...development” – such that classification as Category 1B would be appropriate.
6. Further, the pre-natal developmental toxicity dataset does not support a Category 2 classification: “substances are classified in Category 2...when there is some evidence from humans or experimental animals...of an adverse effect...on development, and where the evidence is not sufficiently convincing to place the substance in Category 1. If deficiencies in the study make the quality of evidence less convincing, Category 2 could be the more appropriate classification.” No meaningful credibility can be ascribed to the 2002 rat study considering incongruent findings and availability of other study data. Therefore, classification as Category 2 is also not supported.

Therefore, based on the weight of evidence, classification of Clomazone for developmental toxicity is not warranted.

A PDF file with this comment has been uploaded as an attachment.

ECHA note – An attachment was submitted with the comment above. Refer to public attachment Clomazone Targeted Public Consultation, FMC, June 7, 2019, final.pdf

RAC’s response

Noted, thank you.

Date	Country	Organisation	Type of Organisation	Comment number
09.06.2019	Denmark		Individual	3

Comment received

Dear evaluators; the studies already evaluated and found scientific robust in the CLH process provide evidence of clomazone's reproductive harm to humans. Please, do not let yourself be misled by industry's strategy to again present new studies to disqualify the existing studies, which over many years were promoted by industry as being perfectly fine.

ANNEX 3 - RECORDS OF THE TARGETED PUBLIC CONSULTATION ON CLOMAZONE (ISO); 2-(2-CHLOROBENZYL)-4,4-DIMETHYL-1,2-OXAZOLIDIN-3-ONE

Keep in mind that the findings of the existing studies do not disappear, and it was demonstrated that clomazone is reproductive, category 1B.

RAC's response

Noted, thank you.

PUBLIC ATTACHMENTS

1. Clomazone Targeted Public Consultation, FMC, June 7, 2019, final.pdf [Please refer to comment No. 2]